Drugs Controller General India Current Affairs, GK & News

DCGI allows use of “Itolizumab” for moderate to severe COVID-19 cases

On July 11, 2020, the Dugs Controller General of India (DCGI) granted restricted emergency use of Itolizumab for moderate to severe COVI-19 patients. Highlights Itolizumab is a monoclonal antibody that was already approved for chronic plaque psoriasis. The drug will now be used to treat COVID-19 based on clinical trials. The drug was manufactured and ..

Month: 

Category: 

Topics: